Literature DB >> 11127866

Blocking the initiation of coagulation by RNA aptamers to factor VIIa.

C P Rusconi1, A Yeh, H K Lyerly, J H Lawson, B A Sullenger.   

Abstract

The tissue factor/factor VIIa complex is thought to be the primary initiator of most physiologic blood coagulation events. Because of its proximal role in this process, we sought to generate new inhibitors of tissue factor/factor VIIa activity by targeting factor VIIa. We employed a combinatorial RNA library and in vitro selection methods to isolate a high affinity, nuclease-resistant RNA ligand that binds specifically to coagulation factor VII/VIIa. This RNA inhibits the tissue factor-dependent activation of factor X by factor VIIa. Kinetic analyses of the mechanism of action of this RNA suggest that it antagonizes factor VIIa activity by preventing formation of a functional factor VII/tissue factor complex. Furthermore, this RNA significantly prolongs the prothrombin time of human plasma in a dose dependent manner, and has an in vitro half-life of approximately 15 h in human plasma. Thus, this RNA ligand represents a novel class of anticoagulant agents directed against factor VIIa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127866

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  24 in total

1.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 2.  Protein-binding oligonucleotides: the next frontier in antithrombotic therapy.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

Review 3.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

Review 4.  Modulation of the Coagulation Cascade Using Aptamers.

Authors:  Rebecca S Woodruff; Bruce A Sullenger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-27       Impact factor: 8.311

5.  The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa.

Authors:  Anandi Krishnan; Erwin A Vogler; Bruce A Sullenger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

6.  A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.

Authors:  K M Bompiani; D M Monroe; F C Church; B A Sullenger
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

Review 7.  Aptamers as Therapeutics.

Authors:  Shahid M Nimjee; Rebekah R White; Richard C Becker; Bruce A Sullenger
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-01-06       Impact factor: 13.820

Review 8.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

9.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

10.  Antimetastatic potential of PAI-1-specific RNA aptamers.

Authors:  Charlene M Blake; Bruce A Sullenger; Daniel A Lawrence; Yolanda M Fortenberry
Journal:  Oligonucleotides       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.